Partnering to Build
West Africa's
Next Chapter.

RORO Strategic Holdings Ltd is a multi-sector investment holding company incorporated in Ghana, with a founding vision that dates to 2015 in the United States. The holding company is the parent and owner of four Ghana subsidiaries — Moovahub, Carevyon, Rolyx Pharma, and RORO Digital Solutions — currently in launch and development. RORO Holdings Inc. is a technology partner under a Technology Service Agreement and is not the legal issuer. Any private capital discussions, if undertaken, are through RORO Strategic Holdings Ltd only.

The group's founding vision was established in 2015 in the United States. RORO Technology was incorporated in Texas in 2019, providing the group's first formal legal entity. In 2026, RORO Holdings was incorporated in the United States and RORO Strategic Holdings was formally incorporated in Ghana, with all four subsidiaries established in the same year. This represents the culmination of a decade-long strategic build — not an opportunistic startup. The group's leadership team brings combined experience in technology, healthcare, logistics, and financial management.

RORO Strategic Holdings is led by Dr. Roland (Founder and Group Chairman), who holds overall strategic vision and investor relations responsibility. The executive team includes Nii Ashitey (Chief Operating Officer), responsible for day-to-day cross-subsidiary performance; Stephen Quansah (Chief Financial Officer), overseeing capital allocation, financial reporting, and treasury; and Manish Naruka (Chief Technology Officer), leading technology strategy, digital infrastructure, and RORO Digital Solutions.

The two entities are legally connected through a formally executed Technology Service Agreement. Under this agreement, RORO Holdings Inc. provides proprietary technology services, software infrastructure, and digital systems to RORO Strategic Holdings Ltd. This is a contractually governed, arm's-length service relationship with documented commercial terms. RORO Holdings Inc. is not the legal issuer for private investment discussions.

We may engage with family offices, institutional partners, strategic co-investors, and other qualified parties who share our long-term orientation toward West Africa. This page does not constitute an offer to sell or solicitation to buy securities. Any capital discussions, if undertaken, follow our qualification, verification, NDA, and compliance process.

Subject to qualification and formal review, structured arrangements involving a specific subsidiary — Moovahub, Carevyon, Rolyx Pharma, or RORO Digital Solutions — may be discussed on a case-by-case basis. No subsidiary-level opportunity is offered or described publicly on this website.

We do not publish minimums or terms on this website. Any structure, if discussed at all, is evaluated individually following our qualification process and documented through formal legal agreements.

Our long-term model focuses on operational improvement, sector depth, scalable platforms, and intra-group synergies across the portfolio. This describes our corporate strategy — not a public offering, return forecast, or investment recommendation.

RORO Strategic Holdings Ltd operates under Ghanaian corporate law with governance standards modelled on international best practices. The group maintains board-level oversight of all subsidiaries, structured financial reporting, and management accountability frameworks. The Technology Service Agreement with RORO Holdings Inc. adds a layer of cross-border contractual governance. Each portfolio company maintains independent management leadership with clear reporting lines to the holding company. We prioritise financial transparency, audit readiness, and ethical governance as core institutional commitments.

Any formal arrangement with RORO Strategic Holdings Ltd, if undertaken, would be governed by legal agreements drafted under applicable law with qualified counsel. Rights, reporting, and terms are documented in writing prior to any commitment. No arrangement is offered or accepted through this website.

RORO Strategic Holdings Ltd is incorporated under Ghanaian corporate law, administered by the Registrar General's Department of Ghana. Each subsidiary is a separate Ghana entity in launch or development. Sector-specific licences, approvals, and operating authorisations are pursued where required — including pharmaceutical regulation for Rolyx Pharma, healthcare data standards for Carevyon, transport and logistics requirements for Moovahub, and applicable technology guidelines for RORO Digital Solutions. RORO Holdings Inc. is incorporated under Texas state law.

Financial information is not disclosed publicly on this website. Parties who complete qualification, verification, NDA execution, and compliance review may receive restricted materials as appropriate. Financial model with management assumptions and scenario analysis. No audit or assurance is provided unless expressly stated in the materials.

Restricted financial materials, if shared after qualification, consist of management-prepared models and scenario analysis. They are not a financial statement audit, review, compilation, agreed-upon procedures engagement, or independent accountant's report unless a specific delivered document expressly states that scope.

We believe in transparent risk disclosure. Key considerations include: (1) Emerging market risk — Ghana's currency (GHS) and macroeconomic environment carry inherent volatility; (2) Early-stage company risk — our subsidiaries are in growth phase and may not yet be cash-flow positive across all operations; (3) Regulatory risk — sector-specific regulation in healthcare and pharmaceuticals may evolve; (4) Concentration risk — a significant portion of revenues is currently Ghana-dependent. We actively manage these risks through portfolio diversification, conservative capital planning, and our regional expansion strategy.

Primary operations are conducted in Ghanaian Cedis (GHS). The Technology Service Agreement with RORO Holdings Inc. creates a structured USD-denominated obligation, providing a natural cross-currency exposure mechanism. We are developing a formal currency risk management framework as part of our institutional readiness programme. Investors with USD exposure should factor GHS/USD exchange rate risk into their assessment.

Submit a general enquiry through our contact page and include a brief description of your organisation and area of interest. We respond to credible enquiries within 5 business days. No offering materials are shared until qualification, verification, NDA, and compliance steps are completed.

Process steps beyond general enquiry are not published on this website. Qualified parties receive details after completing our qualification gate, verification, NDA execution, and compliance review.

Impact considerations are embedded in our sector focus — healthcare access, medicine availability, logistics infrastructure, and technology development. A formal ESG reporting framework is under development as part of our institutional readiness programme.